183 related articles for article (PubMed ID: 27245608)
1. Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.
Fields AP; Ali SA; Justilien V; Murray NR
Small GTPases; 2017 Jan; 8(1):58-64. PubMed ID: 27245608
[TBL] [Abstract][Full Text] [Related]
2. Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.
Ali SA; Justilien V; Jamieson L; Murray NR; Fields AP
Cancer Cell; 2016 Mar; 29(3):367-378. PubMed ID: 26977885
[TBL] [Abstract][Full Text] [Related]
3. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
[TBL] [Abstract][Full Text] [Related]
4. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
5. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic protein kinase Cι signaling mechanisms in lung cancer: Implications for improved therapeutic strategies.
Yin N; Liu Y; Murray NR; Fields AP
Adv Biol Regul; 2020 Jan; 75():100656. PubMed ID: 31623973
[TBL] [Abstract][Full Text] [Related]
7. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.
Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP
Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040
[TBL] [Abstract][Full Text] [Related]
8. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
[TBL] [Abstract][Full Text] [Related]
10. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y
Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
12. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
13. PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.
Wang Y; Hill KS; Fields AP
Mol Cancer Res; 2013 Dec; 11(12):1624-35. PubMed ID: 24174471
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
Scotti ML; Bamlet WR; Smyrk TC; Fields AP; Murray NR
Cancer Res; 2010 Mar; 70(5):2064-74. PubMed ID: 20179210
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
16. Current therapy of KRAS-mutant lung cancer.
Ghimessy A; Radeczky P; Laszlo V; Hegedus B; Renyi-Vamos F; Fillinger J; Klepetko W; Lang C; Dome B; Megyesfalvi Z
Cancer Metastasis Rev; 2020 Dec; 39(4):1159-1177. PubMed ID: 32548736
[TBL] [Abstract][Full Text] [Related]
17. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
18. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
